TOKYO: Japanese trading and pharmaceutical company Kowa Co Ltd said on Monday anti-parasite drug ivermectin has been found effective for treating the Omicron variant of COVID-19 in a Phase III trial.
The trial found ivermectin has "an antiviral effect" against the variant, Kowa said without providing further details.
The firm has been working with Kitasato University, a medical university in Tokyo.
Clinical trials evaluating the drug, which is used to treat parasites in animals and humans, are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy.
The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration has repeatedly warned against its use.
